BR112022012281A2 - Combinações - Google Patents
CombinaçõesInfo
- Publication number
- BR112022012281A2 BR112022012281A2 BR112022012281A BR112022012281A BR112022012281A2 BR 112022012281 A2 BR112022012281 A2 BR 112022012281A2 BR 112022012281 A BR112022012281 A BR 112022012281A BR 112022012281 A BR112022012281 A BR 112022012281A BR 112022012281 A2 BR112022012281 A2 BR 112022012281A2
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- disease
- compounds
- condition
- inhibitor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940125944 selective estrogen receptor degrader Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952039P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/065409 WO2021127044A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012281A2 true BR112022012281A2 (pt) | 2022-08-30 |
Family
ID=76478095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012281A BR112022012281A2 (pt) | 2019-12-20 | 2020-12-16 | Combinações |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230008362A1 (enExample) |
| EP (1) | EP4069235A4 (enExample) |
| JP (1) | JP7631348B2 (enExample) |
| KR (1) | KR20220119442A (enExample) |
| CN (1) | CN115427042A (enExample) |
| AU (1) | AU2020407070A1 (enExample) |
| BR (1) | BR112022012281A2 (enExample) |
| CA (1) | CA3165472A1 (enExample) |
| IL (1) | IL294080A (enExample) |
| MX (1) | MX2022007626A (enExample) |
| TW (1) | TW202132299A (enExample) |
| WO (1) | WO2021127044A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| EP4431511A4 (en) * | 2021-11-09 | 2025-10-15 | Hangzhou Glubio Pharmaceutical Co Ltd | WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017517520A (ja) | 2014-05-29 | 2017-06-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| KR20200108301A (ko) * | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
-
2020
- 2020-12-16 AU AU2020407070A patent/AU2020407070A1/en active Pending
- 2020-12-16 CA CA3165472A patent/CA3165472A1/en active Pending
- 2020-12-16 IL IL294080A patent/IL294080A/en unknown
- 2020-12-16 CN CN202080095235.7A patent/CN115427042A/zh active Pending
- 2020-12-16 WO PCT/US2020/065409 patent/WO2021127044A1/en not_active Ceased
- 2020-12-16 KR KR1020227025073A patent/KR20220119442A/ko not_active Ceased
- 2020-12-16 JP JP2022538220A patent/JP7631348B2/ja active Active
- 2020-12-16 US US17/757,493 patent/US20230008362A1/en not_active Abandoned
- 2020-12-16 BR BR112022012281A patent/BR112022012281A2/pt unknown
- 2020-12-16 MX MX2022007626A patent/MX2022007626A/es unknown
- 2020-12-16 EP EP20902208.6A patent/EP4069235A4/en active Pending
- 2020-12-18 TW TW109145139A patent/TW202132299A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202132299A (zh) | 2021-09-01 |
| JP2023508328A (ja) | 2023-03-02 |
| WO2021127044A1 (en) | 2021-06-24 |
| KR20220119442A (ko) | 2022-08-29 |
| US20230008362A1 (en) | 2023-01-12 |
| EP4069235A1 (en) | 2022-10-12 |
| JP7631348B2 (ja) | 2025-02-18 |
| AU2020407070A1 (en) | 2022-07-14 |
| CN115427042A (zh) | 2022-12-02 |
| CA3165472A1 (en) | 2021-06-24 |
| EP4069235A4 (en) | 2024-01-10 |
| IL294080A (en) | 2022-08-01 |
| MX2022007626A (es) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012281A2 (pt) | Combinações | |
| BR112022012280A2 (pt) | Combinações | |
| BR112022012283A2 (pt) | Combinações | |
| BR112022012278A2 (pt) | Combinações | |
| BR112022012266A2 (pt) | Combinações | |
| BR112022023254A2 (pt) | Monoterapias e terapias de combinação | |
| PT3883579T (pt) | Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| BR112018000808A2 (pt) | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase | |
| BR112019007144A2 (pt) | compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX382765B (es) | Tratamiento para la colangitis biliar primaria. | |
| BR112017013982A2 (pt) | fármaco de combinação | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| CR20220071A (es) | Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal | |
| BR112021023967A2 (pt) | Compostos tricíclicos |